Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Major advance in the treatment of severe malaria in our region

29.08.2005


A drug derived from an ancient Chinese herb has been shown to reduce the risk of death from severe malaria by a third, potentially saving hundreds of thousands of lives in nations on our doorstep.



A trial in malaria patients from four countries has shown a clear benefit over standard treatment with quinine, says Professor Nicholas Anstey of the Menzies School of Health Research in Darwin, Australia, which participated in the trial in partnership with the Indonesian Ministry of Health.

The regional collaboration between the Indonesian Ministry of Health and Darwin’s Menzies School of Health Research has a joint research facility in Timika in Papua province, eastern Indonesia. Hospitals in Bangladesh, Myanmar (Burma), and India also participated in the study, which was coordinated by the Wellcome Trust Unit in Bangkok, Thailand.


The results of the trial are reported in the latest edition of the international medical journal, Lancet, which is published today.

Quinine has been the standard drug for the treatment of severe malaria in most countries, Professor Anstey said. This new trial clearly shows that artesunate, derived from sweet wormwood, or Artemisia annua, has fewer side effects and is more effective than quinine in preventing death in adults with severe malaria.

In total, 1461 patients with severe malaria were treated with either quinine or artesunate. Of these, 20% were enrolled at the Indonesian Ministry of Health/Menzies field site in Papua province.

There were a third fewer deaths among those receiving artesunate: 15% of seriously ill patients died compared to 22% of those treated with quinine.

"Falciparum malaria, the most severe form of the infection, is a major cause of death in our region. At least 120 million cases of falciparum malaria occur in South East Asia each year," Professor Anstey said.

"The reduction in mortality from severe malaria associated with artesunate therapy is excellent news for the poorest communities of the region," he said. "This is the first time that any drug has been demonstrated to be better than quinine at saving lives since the latter was first introduced into Europe nearly 400 years ago."

As a result of this study the Indonesian Ministry of Health has already decided to change national drug policy for treatment of severe malaria from quinine to artesunate.

"The major aim of our collaborative studies in Papua with the Indonesian Ministry of Health is to improve the treatment of malaria and to provide information to policy makers," Professor Anstey said. "We were pleased that the participation of the Indonesian Ministry of Health/Menzies field site in this multi-centre study has contributed to national policy change."

Professor Anstey said a key feature of the trial was the collaboration of dozens of investigators in the four Asian countries, coordinated by Dr Arjen Dondorp and Professor Nick White at the Wellcome Trust Unit at Mahidol University in Bangkok.

The Principal investigator from the Indonesian Ministry of Health was Dr Emiliana Tjitra. The Indonesian Ministry of Health and Menzies School of Health Research contributed a joint team of 13 staff at their research site in Papua Province.

The trials, conducted between June 2003 and May 2005, were funded by a grant from the Wellcome Trust and coordinated as part of the Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme funded by the Wellcome Trust of Great Britain.

Alison Ellis | EurekAlert!
Further information:
http://www.researchaustralia.com.au/
http://www.menzies.edu.au

More articles from Health and Medicine:

nachricht Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo

nachricht Chronic stress induces fatal organ dysfunctions via a new neural circuit
21.08.2017 | Hokkaido University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Molecular volume control

22.08.2017 | Life Sciences

When fish swim in the holodeck

22.08.2017 | Life Sciences

Biochemical 'fingerprints' reveal diabetes progression

22.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>